Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-08052667 |
| Synonyms | |
| Therapy Description |
PF-08052667 is an antibody-drug conjugate (ADC) comprising an antibody that targets ITGB6 linked to monomethyl auristatin E (MMAE), with optimization for intravesical dosing, which potentially induces increased cytotoxicity in Itgb6-expressing tumor cells (PMID: 42008114). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-08052667 | PF08052667|PF 08052667 | PF-08052667 is an antibody-drug conjugate (ADC) comprising an antibody that targets ITGB6 linked to monomethyl auristatin E (MMAE), with optimization for intravesical dosing, which potentially induces increased cytotoxicity in Itgb6-expressing tumor cells (PMID: 42008114). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07206225 | Phase I | PF-08052667 BCG solution + PF-06801591 + PF-08052667 PF-06801591 + PF-08052667 | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Recruiting | USA | ISR | GBR | FRA | ESP | 1 |